Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity
- 20 January 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (4) , 1033-1058
Abstract
Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, enzyme thermostabilization, and lysosomal translocation of GC.Keywords
This publication has 33 references indexed in Scilit:
- Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 studyBlood, 2010
- Rescue of Glaucoma-Causing Mutant Myocilin Thermal Stability by Chemical ChaperonesACS Chemical Biology, 2010
- Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activatorsEuropean Journal of Medicinal Chemistry, 2010
- Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher DiseaseThe Journal of Pediatrics, 2008
- Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher diseaseProceedings of the National Academy of Sciences, 2007
- Enzyme enhancement activity of N-octyl-β-valienamine on β-glucosidase mutants associated with Gaucher diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
- Isofagomine- and 2,5-Anhydro-2,5-imino-d-glucitol-Based Glucocerebrosidase Pharmacological Chaperones for Gaucher Disease InterventionJournal of Medicinal Chemistry, 2006
- The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanismsProceedings of the National Academy of Sciences, 2006
- Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical librariesProceedings of the National Academy of Sciences, 2006
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991